Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04885374
Recruiting Observational

China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine

NCT04885374 · tracked via the Priya Life Science China tracker
Sponsor
Dongzhimen Hospital, Beijing
Phase
Observational
Started
2021-03-01
Last updated
2021-05-13

Condition(s) studied

Amyotrophic Lateral Sclerosis

Study summary

A multi-center registration study of clinical characteristics of amyotrophic lateral sclerosis (ALS) patients with traditional Chinese medicine (TCM).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years and older. * Patients with possible, laboratory supported probable, probable, or definite ALS according to the revised El Escorial criteria. * ALS patients treated with traditional Chinese medicine. Exclusion Criteria: * Patients who refuse informed consent.

Primary outcome measure(s)

  • Effective Survival — Through study completion, an average of 3 months
    The time from disease onset to death, tracheostomy, or permanent assisted ventilation

Trial sites (1)

FacilityCityRegionStatus
Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China Recruiting

More Dongzhimen Hospital, Beijing trials in China

Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency Recruiting
The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula Recruiting
Songling Xuemaikang Capsules for Cerebral Small Vessel Disease Starting soon
Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis Starting soon
The Effect of Sequential Therapy on Alzheimer's Disease Recruiting

Other trials for the same condition

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS Active, not recruiting
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis Recruiting
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis Starting soon
Research on Wireless Brain Implant System for General Control of External Devices Recruiting
A Registered Cohort Study on Amyotrophic Lateral Sclerosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04885374 on ClinicalTrials.gov ↗ ← All trials in China